Insider · CIK 0001222012
Noubar Afeyan
directorowner
Files at MRNA (Moderna, Inc.), GENB (Generate Biomedicines, Inc.). First filing Dec 15, 2025, latest Mar 2, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
2 / 1
$150M bought, $703k sold
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
GENB: Generate Biomedicines, Inc.
GENBOct 9, 2026 · close 14.34
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
MRNA: Moderna, Inc.
MRNAOct 9, 2026 · close 225.00
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | GENBbuy Generate Biomedicines, Inc. | $75M 4,687,500 shares | +34% | 0% from low-4% from high | |
| 56Moderate | GENBbuy Generate Biomedicines, Inc. | $75M 4,687,500 shares | +34% | 0% from low-4% from high | |
| 49Moderate | Moderna, Inc. | $703k 23,853 shares | -86% | +33% from low-38% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Common Stockindirect: By Flagship Pioneering Fund VI, L.P. | +12,723,940 | - | - | 12,723,940 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Common Stockindirect: By Flagship Pioneering Fund VI, L.P. | +12,723,940 | - | - | 12,723,940 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Common Stockindirect: By Flagship Pioneering Fund VII, L.P. | +13,702,224 | - | - | 13,702,224 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Common Stockindirect: By Flagship Pioneering Fund VII, L.P. | +13,702,224 | - | - | 13,702,224 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Common Stockindirect: By Nutritional Health LTP Fund, L.P. | +987,491 | - | - | 987,491 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Common Stockindirect: By Nutritional Health LTP Fund, L.P. | +987,491 | - | - | 987,491 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Common Stockindirect: By Flagship Pioneering Special Opportunities Fund II, L.P. | +2,777,752 | - | - | 2,777,752 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Common Stockindirect: By Flagship Pioneering Special Opportunities Fund II, L.P. | +2,777,752 | - | - | 2,777,752 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Common Stockindirect: By FPN II, L.P. | +2,777,752 | - | - | 2,777,752 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Common Stockindirect: By FPN II, L.P. | +2,777,752 | - | - | 2,777,752 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | POpen-market purchase Common Stockindirect: By Flagship Pioneering Fund VII, L.P. | +1,562,500 | $16.00 | $25M | 15,264,724 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | POpen-market purchase Common Stockindirect: By Flagship Pioneering Fund VII, L.P. | +1,562,500 | $16.00 | $25M | 15,264,724 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | POpen-market purchase Common Stockindirect: By FPN II, L.P. | +1,562,500 | $16.00 | $25M | 4,340,252 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | POpen-market purchase Common Stockindirect: By FPN II, L.P. | +1,562,500 | $16.00 | $25M | 4,340,252 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | POpen-market purchase Common Stockindirect: By Pioneering Medicines 02, LLC | +1,562,500 | $16.00 | $25M | 1,562,500 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | POpen-market purchase Common Stockindirect: By Pioneering Medicines 02, LLC | +1,562,500 | $16.00 | $25M | 1,562,500 | Mar 2, 2026 |
| Feb 26, 2026 | GENB Generate Biomedicines, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Feb 26, 2026 | GENB Generate Biomedicines, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series A Preferred Stockderivativeindirect: By Flagship Pioneering Fund VI, L.P. | -18,483,785 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series A Preferred Stockderivativeindirect: By Flagship Pioneering Fund VI, L.P. | -18,483,785 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series A Preferred Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | -17,016,215 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series A Preferred Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | -17,016,215 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series A Preferred Stockderivativeindirect: By Nutritional Health LTP Fund, L.P. | -1,500,000 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series A Preferred Stockderivativeindirect: By Nutritional Health LTP Fund, L.P. | -1,500,000 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series B Preferred Stockderivativeindirect: By Flagship Pioneering Fund VI, L.P. | -843,881 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series B Preferred Stockderivativeindirect: By Flagship Pioneering Fund VI, L.P. | -843,881 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series B Preferred Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | -1,265,822 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series B Preferred Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | -1,265,822 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series B Preferred Stockderivativeindirect: By Flagship Pioneering Special Opportunities Fund II, L.P. | -2,953,586 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series B Preferred Stockderivativeindirect: By Flagship Pioneering Special Opportunities Fund II, L.P. | -2,953,586 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series B Preferred Stockderivativeindirect: By FPN II, L.P. | -2,109,704 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series B Preferred Stockderivativeindirect: By FPN II, L.P. | -2,109,704 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series C Preferred Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | -2,531,644 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series C Preferred Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | -2,531,644 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series C Preferred Stockderivativeindirect: By Flagship Pioneering Special Opportunities Fund II, L.P. | -1,265,822 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series C Preferred Stockderivativeindirect: By Flagship Pioneering Special Opportunities Fund II, L.P. | -1,265,822 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series C Preferred Stockderivativeindirect: By FPN II, L.P. | -2,109,704 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | GENB Generate Biomedicines, Inc. | CConversion Series C Preferred Stockderivativeindirect: By FPN II, L.P. | -2,109,704 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Dec 11, 2025 | MRNA Moderna, Inc. | MOption exercise Common Stockindirect: By Flagship Pioneering, Inc. | +23,853 | $10.90 | $260k | 27,777 | Dec 15, 2025 |
| Dec 11, 2025 | MRNA Moderna, Inc. | SOpen-market sale Common Stockindirect: By Flagship Pioneering, Inc. | -23,853 | $29.49 | $703k | 3,924 | Dec 15, 2025 |
| Dec 11, 2025 | MRNA Moderna, Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: By Flagship Pioneering, Inc. | -23,853 | $0.00 | $0 | 0 | Dec 15, 2025 |
| Apr 30, 2025 | MRNA Moderna, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,512 | $0.00 | $0 | 25,512 | May 1, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.